Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 31, 2003. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and does not contain comprehensive financial results for the period.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to employee benefit plans and director interests.
Material Changes
The filing details specific movements in shareholdings within employee trusts and retirement plans that affect directors' potential interests:
- US Retirement Savings Plan: On March 27, 2003, the number of Ordinary Share ADRs held by the fund decreased from 18,619,074 to 18,529,080 at an average price of $36.86.
- GSK Employee Trust: On March 28, 2003, 10,200 Ordinary Shares were transferred from the trust to participants of the Glaxo Wellcome 1999 Long Term Incentive Plan.
- SmithKline Beecham Employee Benefit Trust: On March 28, 2003, 38,319 Ordinary Shares were transferred from the trust to participants of the SmithKline Beecham 1991 Share Option Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a procedural disclosure regarding director interests under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Investor Verification Points
- Verify the total aggregate impact of these specific trust transfers on the company's outstanding share count.
- Confirm the specific ownership percentages of Directors Dr. J-P Garnier and Mr. J.D. Coombe resulting from their potential interest in these discretionary funds.
- Review the company's Form 20-F for the full financial performance data for the period ending March 31, 2003, as it is not included in this 6-K.